ClinicalTrials.gg

Program

linvoseltamab

Also written as “Linvoseltamab” and “REGN7945+Linvoseltamab”.

Its studies are mostly in Multiple Myeloma · Immunoglobulin Light-chain Amyloidosis · Monoclonal Gammopathy of Undetermined Significance · Food Hypersensitivity · Smoldering Multiple Myeloma, led by Regeneron Pharmaceuticals.

Furthest: phase 4, since May 20, 202613 company-led studies, 12 open or runningNext primary completion: Aug 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals1312 open or runningphase 4since May 20, 2026Nov 29, 2018Aug 31, 2027phase 1 · NCT06369467

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 29, 2018First study: phase 2 study in Multiple MyelomaFirst studyNCT03761108 · 387 planned · United States, Belgium, Germany and more
  2. Feb 6, 2023Phase 3 study in Multiple MyelomaNCT05730036 · 410 planned · United States, Australia, Belgium and more
  3. Apr 12, 2023Phase 2 study in Multiple MyelomaNCT05828511 · 148 enrolled · United States, France, Spain
  4. Jul 13, 2023Phase 2 study in Smoldering Multiple MyelomaNCT05955508 · 40 enrolled · Spain
  5. Oct 31, 2023Phase 2 study in Monoclonal Gammopathy of Undetermined SignificanceNCT06140524 · 116 planned · United States, Belgium, France and more
  6. Feb 27, 2024Phase 2 study in RecurrenceNCT06292780 · 220 planned · United States, Greece, South Korea and more
  7. Apr 11, 2024Phase 1 study in Food HypersensitivityNCT06369467 · 6 enrolled · United States
  8. Oct 30, 2024Phase 2 study in Multiple MyelomaNCT06669247 · 186 planned · Australia, United Kingdom
  9. Oct 28, 2025Phase 3 study in Relapsed and/or Refractory Multiple Myeloma (RRMM)NCT07222761 · 915 planned · United States, Australia, Brazil and more
  10. Jan 29, 2026Phase 3 study in Multiple MyelomaNCT07393282 · 270 planned · United States, France, Japan and more
  11. Feb 3, 2026Phase 3 study in Multiple MyelomaNCT07428369
  12. May 20, 2026Phase 4 study in Multiple MyelomaNCT07609940 · 30 planned · United States
  13. Oct 22, 2026Phase 3 study in Immunoglobulin Light-chain AmyloidosisNCT07901725 · 382 planned

Ahead

  1. Aug 31, 2027Primary completion: phase 1 study in Food HypersensitivityNCT06369467
  2. Oct 11, 2027Primary completion: phase 4 study in Multiple MyelomaNCT07609940
  3. Aug 20, 2028Primary completion: phase 2 study in RecurrenceNCT06292780
  4. May 21, 2029Primary completion: phase 3 study in Relapsed and/or Refractory Multiple Myeloma (RRMM)NCT07222761

TargetBeta

“A human, immunoglobulin G4 (IgG4) bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
teclistamabruleJohnson & Johnsonphase 411
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 37
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
cizutamigruleUCBphase 25
vonsetamigruleRegeneron Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rulekelonia-therapeutics-incphase 11

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07901725Immunoglobulin Light-chain Amyloidosis3Not yet recruitingJul 25, 2035382
NCT07609940Multiple Myeloma · United States4RecruitingOct 11, 202730
NCT07428369Multiple Myeloma3WithdrawnMay 21, 20380
NCT07393282Multiple Myeloma · United States, France, Japan and more3RecruitingJul 27, 2033270
NCT07222761Relapsed and/or Refractory Multiple Myeloma (RRMM) · United States, Australia, Brazil and more3RecruitingMay 21, 2029915
NCT06669247Multiple Myeloma · Australia, United Kingdom2RecruitingNov 11, 2033186
NCT06369467Food Hypersensitivity · United States1Active, not recruitingAug 31, 20276
NCT06292780Recurrence · United States, Greece, South Korea and more2RecruitingAug 20, 2028220
NCT06140524Monoclonal Gammopathy of Undetermined Significance · United States, Belgium, France and more2RecruitingMay 18, 2032116
NCT05955508Smoldering Multiple Myeloma · Spain2Active, not recruitingJan 25, 203340
NCT05828511Multiple Myeloma · United States, France, Spain2Active, not recruitingNov 2, 2035148
NCT05730036Multiple Myeloma · United States, Australia, Belgium and more3RecruitingApr 19, 2033410
NCT03761108Multiple Myeloma · United States, Belgium, Germany and more2RecruitingMar 30, 2033387

How it is read

Names in the registry

  • “Linvoseltamab”, 12 entries
  • “REGN7945+Linvoseltamab”, 1 entry
  • “linvoseltamab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.